Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CollPlant Biotechnologies (CLGN) Income from Continuing Operations (2017 - 2025)

CollPlant Biotechnologies filings provide 9 years of Income from Continuing Operations readings, the most recent being 2821000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 25.41% to 2821000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 1282000.0, a 268.46% decrease, with the full-year FY2025 number at 11103000.0, up 32.76% from a year prior.
  • Income from Continuing Operations hit 2821000.0 in Q4 2025 for CollPlant Biotechnologies, up from 3483000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 10143000.0 in Q1 2021 to a low of 4676000.0 in Q4 2022.
  • Median Income from Continuing Operations over the past 5 years was 2938000.0 (2021), compared with a mean of 87750.0.
  • Biggest five-year swings in Income from Continuing Operations: surged 735.13% in 2021 and later tumbled 191.07% in 2022.
  • CollPlant Biotechnologies' Income from Continuing Operations stood at 3804000.0 in 2021, then dropped by 22.92% to 4676000.0 in 2022, then increased by 6.03% to 4394000.0 in 2023, then grew by 13.93% to 3782000.0 in 2024, then increased by 25.41% to 2821000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 2821000.0 (Q4 2025), 3483000.0 (Q3 2025), and 3178000.0 (Q2 2025) per Business Quant data.